Your browser doesn't support javascript.
loading
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial.
Eggermont, Alexander M M; Kicinski, Michal; Blank, Christian U; Mandala, Mario; Long, Georgina V; Atkinson, Victoria; Dalle, Stéphane; Haydon, Andrew; Khattak, Adnan; Carlino, Matteo S; Sandhu, Shahneen; Larkin, James; Puig, Susana; Ascierto, Paolo A; Rutkowski, Piotr; Schadendorf, Dirk; Koornstra, Rutger; Hernandez-Aya, Leonel; Di Giacomo, Anna Maria; van den Eertwegh, Alfonsus J M; Grob, Jean-Jacques; Gutzmer, Ralf; Jamal, Rahima; Lorigan, Paul C; Krepler, Clemens; Ibrahim, Nageatte; Marreaud, Sandrine; van Akkooi, Alexander; Robert, Caroline; Suciu, Stefan.
Afiliação
  • Eggermont AMM; Gustave Roussy Cancer Campus Grand Paris, Universite Paris-Saclay, Villejuif, France.
  • Kicinski M; European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium.
  • Blank CU; Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.
  • Mandala M; Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy.
  • Long GV; Melanoma Institute Australia, University of Sydney and Mater and Royal North Shore Hospitals, Sydney, New South Wales, Australia.
  • Atkinson V; Princess Alexandra Hospital, University of Queensland, Brisbane, Queensland, Australia.
  • Dalle S; Hospices Civils de Lyon Cancer Institute, Lyon University, Lyon, France.
  • Haydon A; Alfred Hospital, Melbourne, Victoria, Australia.
  • Khattak A; Fiona Stanley Hospital, University of Western Australia, Perth, Washington, Australia.
  • Carlino MS; Westmead and Blacktown Hospitals, Melanoma Institute Australia and the University of Sydney, New South Wales, Australia.
  • Sandhu S; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Larkin J; Royal Marsden Hospital, London, United Kingdom.
  • Puig S; Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain.
  • Ascierto PA; Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy.
  • Rutkowski P; Maria Sklodowska-Curie Institute Cancer Centre and Institute of Oncology, Warsaw, Poland.
  • Schadendorf D; University Hospital Essen, Essen, Germany.
  • Koornstra R; Germany and German Cancer Consortium of Translational Cancer Research, Heidelberg, Germany.
  • Hernandez-Aya L; Radboud University Medical Center Nijmegen, Nijmegen, Netherlands.
  • Di Giacomo AM; Washington University School of Medicine, St Louis, Missouri.
  • van den Eertwegh AJM; Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy.
  • Grob JJ; Vrije Universiteit Medical Center Amsterdam, Amsterdam, Netherlands.
  • Gutzmer R; Hopital de la Timone, Aix-Marseille University, Marseille, France.
  • Jamal R; Skin Cancer Center, Hannover Medical School, Hannover, Germany.
  • Lorigan PC; Centre de Recherche, Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada.
  • Krepler C; Christie NHS Foundation Trust, Manchester, United Kingdom.
  • Ibrahim N; Merck & Co, Kenilworth, New Jersey.
  • Marreaud S; Merck & Co, Kenilworth, New Jersey.
  • van Akkooi A; European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium.
  • Robert C; Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.
  • Suciu S; Gustave Roussy Cancer Campus Grand Paris, Universite Paris-Saclay, Villejuif, France.
JAMA Oncol ; 6(4): 519-527, 2020 04 01.
Article em En | MEDLINE | ID: mdl-31895407
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Monoclonais Humanizados / Melanoma / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Guideline / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: JAMA Oncol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: França
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Monoclonais Humanizados / Melanoma / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Guideline / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: JAMA Oncol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: França